Number of the records: 1
Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"
- Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE" / Sufliarsky J. -- Ann Oncol, 2017, Sep 18
In Onkológia. -- Bratislava : SOLEN, 2017. -- s. 309-382. -- ISSN 1336-8176. -- Roč. 12, č. 5 (2017), s. 379
1. sarkóm svetlobunkový - genetika - farmakoterapia 2. proteíntyrozínkinázy - antagonisty a inhibítory 3. proteíny protoonkogénové c-met 4. proteín EWS viažuci sa na RNA - genetika 5. prežívanie bez choroby 6. abstrakt v angličtine
I. Šufliarsky, Jozef
II. Redakcia Onkológia
III. Onkológia. -- Roč. 12, č. 5 (2017), s. 379
krizotinib
Number of the records: 1